News
A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring ...
Biopharmaceutical company Biocon is planning to submit a request for approval of generic copies of the blockbuster ...
Zacks Investment Research on MSN7h
Amgen vs. Novo Nordisk: Which Pharma Giant Is the Better Buy?Amgen AMGN and Novo Nordisk NVO are among the largest companies in the pharmaceutical space. Amgen boasts one of the largest ...
In advance of CMS’ negotiated price for the blood thinner taking effect next year, partners Bristol Myers Squibb and Pfizer ...
Some health experts view GLP-1s as a promising option for PCOS, which lacks a standard treatment and affects millions of ...
Biocon aims to launch generic copies of the blockbuster weight-loss drug Wegovy in India and Canada within the next two years, a top executive told Reuters ...
Eli Lilly is tagging along on actress Kym Whitley’s blockbuster summer in a fresh Zepbound partnership with the “Happy ...
Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...
Zacks Investment Research on MSN6d
Eli Lilly vs. Merck: Which Drug Giant Appears Better Poised Today?Both Eli Lilly LLY and Merck MRK are major players in the U.S. pharmaceutical industry, developing and commercializing ...
3don MSN
Industry-Wide Tariffs Loom Over the Healthcare Sector. Here Are 2 Stocks That Can Weather the Storm.
University of Florida researchers said a new study could lead to a universal cancer shot, while digital health earnings ...
New Scientist on MSN6d
You don't need to take drugs like Ozempic consistently to lose weightPeople who take GLP-1 drugs like Ozempic can lose weight even if they face disruptions in accessing the medications, which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback